论文部分内容阅读
为拓宽131I治疗巨大甲状腺功能亢进(甲亢)的适应症提供临床资料，将近几年来131I 治疗巨大甲状腺肿大伴甲亢163例进行了总结，本组病例均采取一次性足量口服，为了最大 程度减少副反应，在治疗前后均予抗甲状腺药物治疗，仅部分患者(92例次）出现副反应， 而131I治疗巨大甲状腺肿大伴甲亢的总有效率为97．5％，1年内的甲状腺功能低下(甲低)发 生率为9．2％，均与131I治疗中度甲状腺肿大伴功能亢进的文献报道相当。因此，131I对 中 度、巨大甲状腺肿大伴甲亢的患者均可首选，具有方法简便、疗效好、安全和无痛苦等 优点 。
To broaden the 131I treatment of hyperthyroidism (hyperthyroidism) indications provide clinical information, in recent years 131I treatment of giant goiter with hyperthyroidism 163 cases were summarized in this group of patients take a full amount of oral, in order to minimize the vice Reaction, before and after treatment were anti-thyroid drug treatment, only some patients (92 cases) side effects, and 131I treatment of giant goiter with hyperthyroidism, the total effective rate was 97.5%, 1 year of hypothyroidism (A Low) incidence of 9.2%, both with 131I treatment of moderate goiter with hyperthyroidism reported in the literature. Therefore, 131I is the first choice for patients with moderate and large goiter with hyperthyroidism, and has the advantages of simple method, good curative effect, safety and no pain.